Evolocumab Repatha®
The SHIKARI® Evolocumab portfolio combines quantitative free-drug measurement with qualitative anti-evolocumab antibody screening for method-controlled research.
Why Evolocumab is relevant to biological-drug monitoring research
Evolocumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Evolocumab is a fully human IgG2 monoclonal antibody that binds PCSK9, increasing recycling of LDL receptors and enhancing clearance of circulating LDL cholesterol. Source ↗
Approved Indications
EMA-authorised uses include primary hypercholesterolaemia, mixed dyslipidaemia, homozygous familial hypercholesterolaemia and reduction of cardiovascular risk in patients with established atherosclerotic cardiovascular disease under defined conditions. EMA source ↗
Steady-State Trough Exposure
FDA pharmacokinetic data report trough accumulation under the two common dosing schedules:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Two verified Evolocumab research assays
Ligand-binding ELISA for quantitative analysis of free evolocumab in human serum or plasma.
Qualitative ELISA for reactive or non-reactive assessment of anti-evolocumab antibodies using assay-specific cut-off interpretation.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-EVO | EVO-FD-REP | Quantitative | Free evolocumab | Human serum / plasma | 10 µL | 140 min | LOD 6 ng/mL; LOQ 6.25 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATEVO | EVO-QLS-REP | Qualitative | Anti-evolocumab antibodies | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Evolocumab Literature and Product-Use Records
Planning a Evolocumab research study?
Matrix Biotek can help identify the appropriate Evolocumab assay and prepare regional quotation and delivery information.